NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $9.77 -0.05 (-0.51%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$9.90 +0.13 (+1.33%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Puma Biotechnology Stock (NASDAQ:PBYI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$9.65▼$9.9050-Day Range$7.69▼$9.8252-Week Range$4.57▼$9.98Volume261,946 shsAverage Volume294,340 shsMarket Capitalization$504.33 millionP/E Ratio18.79Dividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family. In the United States, NERLYNX is approved for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab-based therapy. The product is also approved for certain adults with advanced or metastatic HER2-positive breast cancer after two or more prior anti-HER2-based regimens. Puma continues to evaluate neratinib in additional cancer settings and treatment combinations. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology operates primarily in oncology and commercializes NERLYNX directly in the United States while working with international partners in selected markets. Alan H. Auerbach serves as the company’s founder, chief executive officer and president.AI Generated. May Contain Errors. Read More Puma Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 24% of companies evaluated by MarketBeat, and ranked 802nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.Downside RiskPuma Biotechnology has a consensus price target of $6.00, representing about 38.6% downside from its current price of $9.77.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-62.16% Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -62.16% in the coming year, from $0.37 to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 18.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 18.79, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.76% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 1.06%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentPuma Biotechnology has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.Search Interest3 people have searched for PBYI on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,046,107.00 in company stock.Percentage Held by Insiders22.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBYI Stock News HeadlinesPuma Biotechnology (NASDAQ:PBYI) Reaches New 52-Week High - Should You Buy?September 24 at 5:41 AM | americanbankingnews.comPuma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung CancerSeptember 18, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 27 at 1:00 AM | Stansberry Research (Ad)Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung CancerSeptember 18, 2026 | tipranks.comAlessandra Cesano Sells 62,150 Shares of Puma Biotechnology (NASDAQ:PBYI) StockSeptember 18, 2026 | americanbankingnews.comPuma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung CancerSeptember 17, 2026 | businesswire.comInsider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $45,500.00 in StockSeptember 17, 2026 | insidertrades.comPuma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment ConferenceSeptember 9, 2026 | finance.yahoo.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $5.95 at the start of the year. Since then, PBYI shares have increased by 64.2% and is now trading at $9.77. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.15. The biopharmaceutical company earned $56.50 million during the quarter, compared to the consensus estimate of $53 million. Puma Biotechnology had a trailing twelve-month return on equity of 20.76% and a net margin of 11.50%. Read the conference call transcript. Who are Puma Biotechnology's major shareholders? Top institutional shareholders of Puma Biotechnology include BlackRock Inc. (7.47%), Connor Clark & Lunn Investment Management Ltd. (1.25%), Globeflex Capital L P (0.74%) and Bank of New York Mellon Corp (0.71%). Insiders that own company stock include Alan H Auerbach, Douglas M Hunt, Maximo F Nougues, Brian M Stuglik, Jeffrey Jerome Ludwig, Alvin F Wong, Allison Dorval, Jay M Moyes, Alessandra Cesano, Troy Edward Wilson, Michael Patrick Miller and Adrian Senderowicz. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2026Today9/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PBYI's financial health is in the Green zone, according to TradeSmith. PBYI has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PBYI CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees179Year Founded2010Price Target and Rating Average Price Target for Puma Biotechnology$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside-38.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.52 Trailing P/E Ratio18.79 Forward P/E Ratio26.41 P/E GrowthN/ANet Income$31.11 million Net Margins11.50% Pretax Margin13.48% Return on Equity20.76% Return on Assets13.22% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.64 Sales & Book Value Annual Sales$228.40 million Price / Sales2.21 Cash Flow$0.83 per share Price / Cash Flow11.71 Book Value$2.59 per share Price / Book3.77Miscellaneous Outstanding Shares51,620,000Free Float40,160,000Market Cap$504.33 million OptionableOptionable Beta1.24 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PBYI) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
